Logotipo del repositorio
Logotipo del repositorio
 

Impact of HbA1c reduction on major kidney outcomes in type 2 diabetes with poor glycemic control and advanced CKD

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2
dc.contributor.authorNavarro Blackaller, Guillermo
dc.contributor.authorBenitez-Renteria, A. S.
dc.contributor.authorHernández-Morales, K.
dc.contributor.authorRico-Fontalvo, Jorge
dc.contributor.authorDaza-Arnedo, R.
dc.contributor.authorGómez-Ramírez, G. G.
dc.contributor.authorCamacho-Guerrero, J. R.
dc.contributor.authorPérez-Venegas, M. A.
dc.contributor.authorCarmona-Morales, J.
dc.contributor.authorOseguera-González, A. N.
dc.contributor.authorMurguía Soto, César
dc.contributor.authorChávez-Alonso, G.
dc.contributor.authorGarcía-Peña, F.
dc.contributor.authorBarrera-Torres, C. J.
dc.contributor.authorOrozco-Chan, E.
dc.contributor.authorArredondo-Dubois, M.
dc.contributor.authorMartínez Gallardo González, Alejandro
dc.contributor.authorGómez-Fregoso, J. A.
dc.contributor.authorRodríguez-García, F. G.
dc.contributor.authorLuquin-Arellano, V. H.
dc.contributor.authorAbundis-Mora, G.
dc.contributor.authorAlcantar-Vallin, L.
dc.contributor.authorMedina-González, R.
dc.contributor.authorGarcía-García, G.
dc.contributor.authorChávez-Iñiguez, Jonathan S.
dc.date.accessioned2025-05-07T22:44:04Z
dc.date.available2025-05-07T22:44:04Z
dc.date.issued2025
dc.description.abstractAims: In subjects with type 2 diabetes (DM), poor glycemic control, and advanced chronic kidney disease (CKD), the kidney beneft of the reduction of glycated hemoglobin (HbA1c) is not well established. Methods: In a retrospective cohort, we included patients with DM, CKD grade 3b-5, and HbA1c > 9% to evaluate the risk of developing major adverse kidney events (MAKE) defned as the start of kidney replacement therapy (KRT), ≥ 25% or ≥ 40% decline in the glomerular fltration rate (eGFR) from baseline, and death; patients were divided according to the HbA1c levels at the end of the follow-up into the following groups: > 75 mmol/mol (≥ 9.0%), 74–64 mmol/mol (8.9%–8.0%), 64–53 mmol/mol (7.9%–7.0%), and < 52 mmol/mol (< 7.0%). We described their characteristics and analyzed their risks, adjusting for confounding variables. Results: From 2015 to 2023, 111 patients were included. In 46 patients (41.4%), the HbA1c at the end of follow-up (60 months) was still > 75 mmol/mol (≥ 9%), and each patient had a mean of 4.9 HbA1c measurements. Te mean age was 59 years, and 46% were male; the baseline eGFR was 25 mL/min/1.73 m2 . MAKE occurred in 67% of cases. In a multivariate analysis, the risk of MAKE was not associated with the HbA1c groups, nor was it associated with any of the MAKE components individually, nor in certain subgroups. When evaluating the magnitude of percentage changes in HbA1 with the initiation of KRT, we did not fnd any association. Conclusions: With advanced CKD and poor glycemic control, changes in HbA1c during long follow-up are not associated with MAKE or its individual components.eng
dc.format.mimetypepdf
dc.identifier.citationNavarro-Blackaller, G., Benitez-Renteria, A. S., Hernández-Morales, K., Rico-Fontalvo, J., Daza-Arnedo, R., Gómez-Ramírez, G. G., Camacho-Guerrero, J. R., Pérez-Venegas, M. A., Carmona-Morales, J., Oseguera-González, A. N., Murguía-Soto, C., Chávez-Alonso, G., García-Peña, F., Barrera-Torres, C. J., Orozco-Chan, E., Arredondo-Dubois, M., Gallardo-González, A. Martínez, Gómez-Fregoso, J. A., Rodríguez-García, F. G., Luquin-Arellano, V. H., Abundis-Mora, G., Alcantar-Vallin, L., Medina-González, R., García-García, G., Chávez-Iñiguez, J. S., Impact of HbA1c Reduction on Major Kidney Outcomes in Type 2 Diabetes With Poor Glycemic Control and Advanced CKD, International Journal of Endocrinology, 2025, 9919963, 12 pages, 2025. https://doi.org/10.1155/ije/9919963
dc.identifier.doihttps://doi.org/10.1155/ije/9919963
dc.identifier.issn16878345 (Electrónico)
dc.identifier.issn16878337 (Impreso)
dc.identifier.urihttps://hdl.handle.net/20.500.12442/16553
dc.identifier.urlhttps://onlinelibrary.wiley.com/journal/1573
dc.language.isoeng
dc.publisherWileyeng
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationaleng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceInternational journal of endocrinologyeng
dc.sourceAño 2025spa
dc.subject.keywordsChronic kidney diseaseeng
dc.subject.keywordsDiabeteseng
dc.subject.keywordsKidney replacement therapyeng
dc.subject.keywordsMajor adverse kidney eventseng
dc.subject.keywordsMortalityeng
dc.titleImpact of HbA1c reduction on major kidney outcomes in type 2 diabetes with poor glycemic control and advanced CKDeng
dc.type.driverinfo:eu-repo/semantics/article
dc.type.spaArtículo científico
dcterms.referencesO. Y. Bello-Chavolla, N. E. Antonio-Villa, C. A. Ferm´ın-Mart´ınez, et al., “Diabetes-Related Excess Mortality in Mexico: A Comparative Analysis of National Death Registries Between 2017–2019 and 2020,” Diabetes Care 45, no. 12 (2022): 2957–2966, https://doi.org/10.2337/dc22- 0616.eng
dcterms.referencesL. R. Zelnick, N. S. Weiss, B. R. Kestenbaum, et al., “Diabetes and CKD in the United States Population, 2009–2014,” Clinical Journal of the American Society of Nephrology 12, no. 12 (2017): 1984–1990, https://doi.org/10.2215/ CJN.03700417eng
dcterms.referencesM. Afkarian, M. C. Sachs, B. Kestenbaum, et al., “Kidney Disease and Increased Mortality Risk in Type 2 Diabetes,” Journal of the American Society of Nephrology 24, no. 2 (2013): 302–308, https://doi.org/10.1681/ASN.2012070718.eng
dcterms.referencesL. Tonneijck, M. H. Muskiet, M. M. Smits, et al., “Glomerular Hyperfltration in Diabetes: Mechanisms, Clinical Signifcance, and Treatment,” Journal of the American Society of Nephrology 28, no. 4 (2017): 1023–1039, https://doi.org/ 10.1681/ASN.2016060666.eng
dcterms.referencesH. J. Anders, T. B. Huber, B. Isermann, and M. Schifer, “CKD in Diabetes: Diabetic Kidney Disease Versus Nondiabetic Kidney Disease,” Nature Reviews Nephrology 14, no. 6 (2018): 361–377, https://doi.org/10.1038/s41581-018-0001-y.eng
dcterms.referencesS. A. Amiel, P. Aschner, B. Childs, et al., “Hypoglycaemia, Cardiovascular Disease, and Mortality in Diabetes: Epidemiology, Pathogenesis, and Management,” Lancet Diabetes & Endocrinology 7, no. 5 (2019): 385–396, https://doi.org/ 10.1016/S2213-8587(18)30315-2.eng
dcterms.referencesR. E. Gilbert and P. A. Marsden, “Activated Protein C and Diabetic Nephropathy,” New England Journal of Medicine 358, no. 15 (2008): 1628–1630, https://doi.org/10.1056/ NEJMcibr0801042.eng
dcterms.referencesA. Diez-Sampedro, O. Lenz, and A. Fornoni, “Podocytopathy in Diabetes: A Metabolic and Endocrine Disorder,” American Journal of Kidney Diseases 58, no. 4 (2011): 637–646, https:// doi.org/10.1053/j.ajkd.2011.03.035.eng
dcterms.referencesA. E. Stinghen, Z. A. Massy, H. Vlassara, G. E. Striker, and A. Boullier, “Uremic Toxicity of Advanced Glycation End Products in CKD,” Journal of the American Society of Nephrology 27, no. 2 (2016): 354–370, https://doi.org/10.1681/ ASN.2014101047.eng
dcterms.referencesA. Flyvbjerg, “Te Role of the Complement System in Diabetic Nephropathy,” Nature Reviews Nephrology 13, no. 5 (2017): 311–318, https://doi.org/10.1038/nrneph.2017.31.eng
dcterms.referencesY. Suzuki, H. Kaneko, A. Okada, et al., “Impact of Glucose Tolerance and Its Change on Incident Proteinuria: Analysis of a Nationwide Population-Based Dataset,” American Journal of Nephrology 53, no. 4 (2022): 307–315, https://doi.org/10.1159/ 000522280.eng
dcterms.referencesH. H. Jung, “Evaluation of Serum Glucose and Kidney Disease Progression Among Patients With Diabetes,” JAMA Network Open 4, no. 9 (2021): e2127387, https://doi.org/10.1001/ jamanetworkopen.2021.27387.eng
dcterms.referencesR. J. Galindo, R. W. Beck, M. F. Scioscia, G. E. Umpierrez, and K. R. Tuttle, “Glycemic Monitoring and Management in Advanced Chronic Kidney Disease,” Endocrine Reviews 41, no. 5 (2020): 756–774, https://doi.org/10.1210/endrev/ bnaa017.eng
dcterms.referencesS. D. Navaneethan, J. D. Schold, S. E. Jolly, S. Arrigain, W. C. Winkelmayer, and J. V. Nally Jr, “Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD,” American Journal of Kidney Diseases 70, no. 2 (2017): 191–198, https://doi.org/10.1053/j.ajkd.2016.11.018.eng
dcterms.referencesC. Limkunakul, I. H. de Boer, B. R. Kestenbaum, J. Himmelfarb, T. A. Ikizler, and C. Robinson-Cohen, “Te Association of Glycated Hemoglobin With Mortality and ESKD Among Persons With Diabetes and Chronic Kidney Disease,” Journal of Diabetes and Its Complications 33, no. 4 (2019): 296–301, https://doi.org/10.1016/j.jdiacomp.2018.12.010.eng
dcterms.referencesP. Rossing, M. L. Caramori, J. C. Chan, et al., “KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease,” Kidney International 102, no. 5 (2022): S1–S127, https://doi.org/10.1016/j.kint.2022.06.008.eng
dcterms.referencesK. R. Tuttle, G. L. Bakris, R. W. Bilous, et al., “Diabetic Kidney Disease: A Report From an ADA Consensus Conference,” Diabetes Care 37, no. 10 (2014): 2864–2883, https://doi.org/ 10.2337/dc14-1296.eng
dcterms.referencesM. Oshima, M. Shimizu, M. Yamanouchi, et al., “Trajectories of Kidney Function in Diabetes: A Clinicopathological Update,” Nature Reviews Nephrology 17, no. 11 (2021): 740–750, https://doi.org/10.1038/s41581-021-00462-y.eng
dcterms.referencesL. A. Wright and I. B. Hirsch, “Metrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters,” Diabetes Technology & Terapeutics 19, no. S2 (2017): S-16–S-26, https://doi.org/10.1089/ dia.2017.0029.eng
dcterms.referencesP. E. Stevens and A. Levin, “Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline,” Annals of Internal Medicine 158, no. 11 (2013): 825–830, https://doi.org/10.7326/0003-4819-158-11-201306040-00007.eng
dcterms.referencesE. von Elm, D. G. Altman, M. Egger, et al., “Te Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies,” International Journal of Surgery 12, no. 12 (2014): 1495–1499, https://doi.org/10.1016/j.ijsu.2014.07.013.eng
dcterms.referencesE. I. Benchimol, L. Smeeth, A. Guttmann, et al., “Te Reporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) Statement,” PLoS Medicine 12, no. 10 (Oct 6 2015): e1001885, https:// doi.org/10.1371/journal.pmed.1001885.eng
dcterms.referencesJ. A. Kellum, N. Lameire, and Kdigo AKI Guideline Work Group, “Diagnosis, Evaluation, and Management of Acute Kidney Injury: A KDIGO Summary (Part 1),” Critical Care 17, no. 1 (2013): 204, https://doi.org/10.1186/cc11454.eng
dcterms.referencesS. Negi, D. Koreeda, S. Kobayashi, Y. Iwashita, and T. Shigematu, “Renal Replacement Terapy for Acute Kidney Injury,” Renal Replacement Terapy 2, no. 1 (2016): 31–37, https://doi.org/10.1186/s41100-016-0043-1.eng
dcterms.referencesD. E. Leaf and S. S. Waikar, “IDEAL-ICU in Context,” Clinical Journal of the American Society of Nephrology 14, no. 8 (2019): 1264–1267, https://doi.org/10.2215/CJN.01180119.eng
dcterms.referencesAdvance Collaborative Group, A. Patel, S. MacMahon, et al., “Intensive Blood Glucose Control and Vascular Outcomes in Patients With Type 2 Diabetes,” New England Journal of Medicine 358, no. 24 (2008): 2560–2572, https://doi.org/ 10.1056/NEJMoa0802987.eng
dcterms.referencesW. Duckworth, C. Abraira, T. Moritz, et al., “Glucose Control and Vascular Complications in Veterans With Type 2 International Journal of Endocrinology 11 Diabetes,” New England Journal of Medicine 360, no. 2 (2009): 129–139, https://doi.org/10.1056/NEJMoa0808431.eng
dcterms.referencesF. Ismail-Beigi, T. Craven, M. A. Banerji, et al., “Efect of Intensive Treatment of Hyperglycaemia on Microvascular Outcomes in Type 2 Diabetes: An Analysis of the ACCORD Randomised Trial,” Te Lancet 376, no. 9739 (2010): 419–430, https://doi.org/10.1016/S0140-6736(10)60576-4.eng
dcterms.referencesK. Shikata, M. Haneda, T. Ninomiya, et al., “Randomized Trial of an Intensifed, Multifactorial Intervention in Patients With Advanced-Stage Diabetic Kidney Disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan),” Journal of Diabetes Investigation 12, no. 2 (2021): 207–216, https://doi.org/10.1111/jdi.13339.eng
dcterms.referencesM. Hodge, E. McArthur, A. X. Garg, N. Tangri, and K. K. Clemens, “Hypoglycemia Incidence in Older Adults by Estimated GFR,” American Journal of Kidney Diseases 70, no. 1 (Jul 2017): 59–68, https://doi.org/10.1053/ j.ajkd.2016.11.019.eng
dcterms.referencesS. Hong, L. Presswala, Y. T. Harris, et al., “Hypoglycemia in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Prospective Observational Study,” Kidney 1, no. 9 (2020): 897–903, https://doi.org/10.34067/KID.0001272020.eng
dcterms.referencesM. F. Moen, M. Zhan, V. D. Hsu, et al., “Frequency of Hypoglycemia and Its Signifcance in Chronic Kidney Disease,” Clinical Journal of the American Society of Nephrology 4, no. 6 (2009): 1121–1127, https://doi.org/10.2215/CJN.00800209.eng
dcterms.referencesI. Ahmad, L. R. Zelnick, Z. Batacchi, et al., “Hypoglycemia in People With Type 2 Diabetes and CKD,” Clinical Journal of the American Society of Nephrology 14, no. 6 (2019): 844–853, https://doi.org/10.2215/CJN.11650918.eng
dcterms.referencesY. Xu, S. Dong, E. L. Fu, et al., “Long-Term Visit-To-Visit Variability in Hemoglobin A1c and Kidney-Related Outcomes in Persons With Diabetes,” American Journal of Kidney Diseases 82, no. 3 (May 2023): 267–278, https://doi.org/ 10.1053/j.ajkd.2023.03.007.eng
dcterms.referencesS. De Marchi, E. Cecchin, C. Camurri, et al., “Origin of Glycosylated Hemoglobin Al in Chronic Renal Failure,” Te International Journal of Artifcial Organs 6, no. 2 (1983): 77–82, https://doi.org/10.1177/039139888300600208.eng
dcterms.referencesF. E. Vos, J. B. Schollum, C. V. Coulter, P. J. Manning, S. B. Dufull, and R. J. Walker, “Assessment of Markers of Glycaemic Control in Diabetic Patients With Chronic Kidney Disease Using Continuous Glucose Monitoring,” Nephrology 17, no. 2 (2012): 182–188, https://doi.org/10.1111/j.1440- 1797.2011.01517.x.eng
dcterms.referencesJ. Chavez, G. Garcia-Garcia, R. Medina, et al., “Alejandro. Decrease of Hemoglobin A1c (HbA1c) in Patients With Type 2 Diabetes, Suboptimal Glycemic Control, in Advanced CKD, and Major Adverse Kidney Events: PUB116,” Journal of the American Society of Nephrology 35, no. 10S (2024): https:// doi.org/10.1681/ASN.2024vjf5zt55.eng
oaire.versioninfo:eu-repo/semantics/publishedVersion

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
PDF.pdf
Tamaño:
1.24 MB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca